Stromal Interaction Molecule 1 (STIM1) is a critical endoplasmic reticulum (ER) calcium sensor that plays a pivotal role in Store-Operated Calcium Entry (SOCE). Upon ER calcium depletion, STIM1 oligomerizes and translocates to ER-plasma membrane junctions, where it recruits and activates ORAI1 calcium channels. Dysregulation of the STIM1-ORAI1 pathway is heavily implicated in autoimmune diseases, inflammatory disorders, cardiovascular pathologies, and cancer metastasis, making STIM1 a highly sought-after drug target for small molecule inhibitors and therapeutic modulators.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for STIM1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | STIM1 Cytosolic Domain (SOAR/CAD) Recombinant Protein / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Ideal for protein-protein interaction assays. |
View STIM1 Products |
| Gene Delivery | STIM1 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation. Essential for functional calcium flux screening. |
View STIM1 Products |
| Benchmark Ab | Anti-STIM1 Recombinant Antibody Recombinant positive control for western blot, immunofluorescence, and flow cytometry. |
View STIM1 Products |
| Validator | STIM1 siRNA Set For knockdown verification and target specificity validation in cell-based assays. |
View STIM1 Products |
| Related Target A | ORAI1 The pore-forming subunit of the CRAC channel, directly gated by STIM1. Essential for co-expression and functional SOCE reconstitution. |
View ORAI1 Products |
| Related Target B | TRPC1 Transient receptor potential channel that interacts with STIM1 to modulate store-operated calcium currents. |
View TRPC1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Functional SOCE Reconstitution | High-titer Lentivirus for stable co-expression of STIM1 and ORAI1 in HEK293/Jurkat cells. |
| Protein-Protein Interaction (PPI) Screening | Highly stable STIM1 SOAR domain recombinant proteins, sequence-verified and purity checked by SDS-PAGE. |
| Lack of Controls | Sequence-validated anti-STIM1 benchmark antibodies and positive control expression plasmids. |
| False Positives in Small Molecule Screens | Target-specific siRNA sets included for orthogonal knockdown validation. |
Live STIM1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of STIM1 is rapidly evolving. While early drug discovery efforts focused on broad-spectrum CRAC channel blockers, the current paradigm has shifted toward selective inhibitors of the STIM1-ORAI1 interaction interface. By specifically disrupting the coupling of the STIM1 SOAR/CAD domain to ORAI1, researchers aim to achieve higher tissue selectivity and minimize off-target toxicity associated with systemic calcium channel blockade. Next-generation candidates are expanding from small molecules to peptide mimetics and intracellular delivery modalities targeting STIM1 conformational transitions.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Calcimedica, Synta Pharmaceuticals | Acute Pancreatitis, Plaque Psoriasis, Rheumatoid Arthritis | Calcium Flux Assay (Requires STIM1/ORAI1 Lentivirus for stable cell lines) |
| Peptide Mimetics | Academic Spin-offs | Solid Tumors (Metastasis Inhibition) | In vitro binding assay (Requires high-purity STIM1 SOAR recombinant protein) |
| Gene Therapy / RNAi | Preclinical Biotech Programs | Cardiovascular Hypertrophy | Knockdown efficiency verification (Requires sequence-verified STIM1 siRNA) |